Healius (ASX:HLS) reported Thursday that its underlying loss per diluted share in the fiscal first half narrowed to AU$0.0279, from a loss of AU$0.031 per diluted share a year earlier.
Analysts polled by FactSet were expecting a loss of AU$0.01 per share.
Revenue for the six months ended Dec. 31, 2024, was AU$662.3 million, up from AU$620.8 million in the same period a year earlier. Analysts surveyed by FactSet expected sales of AU$913 million.
The healthcare company expects fiscal 2025 earnings before interest and taxes from Agilex Biolabs to be similar to last year's AU$5.1 million.
The company's shares were down past 4% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.